Merit Medical elected Scott R. Ward to its Board of Directors for a three-year term, enhancing strategic leadership.
Quiver AI Summary
Merit Medical Systems, Inc. announced the election of Scott R. Ward to its Board of Directors during the company's annual shareholder meeting, where he will serve a three-year term. Board Chair F. Ann Millner and CEO Martha G. Aronson praised Ward's extensive experience in the medical device industry, particularly his leadership roles at Medtronic and Cardiovascular Systems, Inc. Ward, who has over 40 years of experience in healthcare, expressed his honor in joining the board and his commitment to contributing to the company's innovation and growth. He will also serve on the Governance and Sustainability and Finance and Operating Committees. Founded in 1987, Merit Medical develops and distributes proprietary medical devices globally, employing approximately 7,600 people.
Potential Positives
- Scott R. Ward's election to the Board of Directors brings over 40 years of healthcare and medical device industry experience, which is a significant asset for the company's strategic priorities.
- Mr. Ward's previous leadership roles at Medtronic and as CEO of Cardiovascular Systems, Inc. suggest a strong background in driving growth and innovation in medical technology, potentially benefiting Merit Medical's future initiatives.
- Merit Medical's commitment to innovation and strategic growth is reinforced by the addition of Mr. Ward, who aligns with the company's mission to serve patients and healthcare providers globally.
Potential Negatives
- There is no mention of any specific challenges or strategic priorities that the company is facing, which could raise concerns about its preparedness for future obstacles.
- The press release does not disclose any recent financial performance data or forecasts, which might leave investors uncertain about the company’s current standing and future growth potential.
- The announcement primarily focuses on the new board member rather than on broader company initiatives or results, which could suggest a lack of significant developments or milestones achieved recently.
FAQ
Who was elected to Merit Medical's Board of Directors?
Scott R. Ward was elected to the Board of Directors at Merit Medical Systems, Inc.
What is Scott R. Ward's experience in the medical device industry?
Scott R. Ward has over 40 years of experience in healthcare and medical devices, including leadership roles at Medtronic and Cardiovascular Systems, Inc.
What committees will Scott Ward serve on at Merit Medical?
Mr. Ward has been appointed to the Governance and Sustainability and Finance and Operating Committees.
What did Merit’s Chair F. Ann Millner say about Scott Ward's election?
F. Ann Millner expressed pleasure with his election and highlighted his extensive industry experience and strategic insight as valuable assets.
When was Scott R. Ward elected to the Board?
Scott R. Ward was elected at Merit Medical's annual meeting of shareholders on May 19, 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MMSI Insider Trading Activity
$MMSI insiders have traded $MMSI stock on the open market 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $MMSI stock by insiders over the last 6 months:
- FRED P. LAMPROPOULOS (Executive Chairman) has made 0 purchases and 4 sales selling 60,000 shares for an estimated $5,189,907.
- NEIL W. PETERSON (CHIEF OPERATING OFFICER) sold 5,000 shares for an estimated $450,000
- CHRISTIAN ADAM SMITH (Chief Commercial Officer) purchased 1,626 shares for an estimated $99,186
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MMSI Revenue
$MMSI had revenues of $381.9M in Q1 2026. This is an increase of 7.46% from the same period in the prior year.
You can track MMSI financials on Quiver Quantitative's MMSI stock page.
You can access data on MMSI stock through the Quiver Quantitative API.
$MMSI Hedge Fund Activity
We have seen 228 institutional investors add shares of $MMSI stock to their portfolio, and 204 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACQUARIE GROUP LTD removed 1,331,579 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $117,365,373
- WELLINGTON MANAGEMENT GROUP LLP removed 1,023,185 shares (-77.1%) from their portfolio in Q1 2026, for an estimated $70,528,142
- FMR LLC removed 766,641 shares (-43.3%) from their portfolio in Q1 2026, for an estimated $52,844,564
- THRIVENT FINANCIAL FOR LUTHERANS removed 683,972 shares (-93.3%) from their portfolio in Q1 2026, for an estimated $47,146,189
- VOYA INVESTMENT MANAGEMENT LLC removed 453,417 shares (-94.7%) from their portfolio in Q1 2026, for an estimated $31,254,033
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 447,451 shares (+inf%) to their portfolio in Q1 2026, for an estimated $30,842,797
- LOOMIS SAYLES & CO L P removed 447,381 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $39,432,161
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MMSI Analyst Ratings
Wall Street analysts have issued reports on $MMSI in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 05/01/2026
- Piper Sandler issued a "Overweight" rating on 02/18/2026
To track analyst ratings and price targets for $MMSI, check out Quiver Quantitative's $MMSI forecast page.
$MMSI Price Targets
Multiple analysts have issued price targets for $MMSI recently. We have seen 7 analysts offer price targets for $MMSI in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Mike Matson from Needham set a target price of $90.0 on 05/01/2026
- Larry Biegelsen from Wells Fargo set a target price of $74.0 on 05/01/2026
- Robbie Marcus from JP Morgan set a target price of $77.0 on 05/01/2026
- Jon Young from Canaccord Genuity set a target price of $85.0 on 05/01/2026
- Michael Petusky from Barrington Research set a target price of $107.0 on 04/20/2026
- Jason Bednar from Piper Sandler set a target price of $96.0 on 04/17/2026
- Sam Eiber from BTIG set a target price of $107.0 on 02/06/2026
Full Release
SOUTH JORDAN, Utah, May 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that shareholders elected Scott R. Ward to the company’s Board of Directors at Merit’s annual meeting of shareholders.
Mr. Ward was elected to serve a three-year term.
“On behalf of the Board, we are pleased with Scott Ward’s election to Merit’s Board of Directors,” said F. Ann Millner, Merit’s Chair of the Board. “Scott’s extensive industry experience, strategic insight, and commitment to innovation will be tremendous assets as we continue advancing the company’s strategic priorities.”
“We are proud to welcome Scott Ward to Merit’s Board,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “Scott brings deep medical device experience and a proven leadership track record. As we continue building on our foundation and advancing our strategy, his perspective will be invaluable to our long-term growth.”
“I am honored to join the Merit Board of Directors,” Ward said. “I have great respect for Merit’s commitment to innovation and its focus on serving patients and healthcare providers around the world. I look forward to contributing my experience as the company continues to grow and expand its impact.”
Mr. Ward brings more than 40 years of experience in the healthcare and medical device industry, including nearly three decades at Medtronic, where he held senior leadership roles such as senior vice president and president of the cardiovascular, neurological, and diabetes businesses. He most recently served as CEO, President and Chairman of Cardiovascular Systems, Inc., leading the company through a period of expansion and its acquisition by Abbott.
Mr. Ward is also the founder of Raymond Holdings, a firm focused on venture capital, strategy, and advisory services for medical technology and life sciences companies, and has served on numerous public and private company boards. Merit’s Board of Directors has appointed Mr. Ward to serve on its Governance and Sustainability and Finance and Operating Committees.
ABOUT MERIT MEDICAL
Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 |
[email protected]
Investor Inquiries
Mike Piccinino, CFA, IRC
ICR Healthcare
+1-443-213-0509 |
[email protected]
